Skip to main navigation
iTeos Therapeutics - Cancer Immunotherapies by Design iTeos Therapeutics - Cancer Immunotherapies by Design

Main Nav

  • Home
  • About us
    • Overview
    • Management team
    • Board of Directors
    • Scientific Advisory Board
    • Partnering
  • Pipeline
    • Pipeline
    • Clinical trials
    • A2A Receptor Antagonist
    • TIGIT antagonist monoclonal antibody
    • Preclinical pipeline
  • Technology
    • Cancer Immunotherapy & Immunosuppression
    • Scientific Publications
  • Investors
    • News & Events
    • Stock Information
    • Financials
    • Governance
    • Investor Resources
  • Join the iTeos Team
  • Contact us

Main Nav

  • Home
  • About us
    • Overview
    • Management team
    • Board of Directors
    • Scientific Advisory Board
    • Partnering
  • Pipeline
    • Pipeline
    • Clinical trials
    • A2A Receptor Antagonist
    • TIGIT antagonist monoclonal antibody
    • Preclinical pipeline
  • Technology
    • Cancer Immunotherapy & Immunosuppression
    • Scientific Publications
  • Investors
    • News & Events
    • Stock Information
    • Financials
    • Governance
    • Investor Resources
  • Join the iTeos Team
  • Contact us
Skip to main content

sub Financials

  • SEC Filings
  • Quarterly Results
  • Annual Reports

SEC Filing

SEC Filing Details

Document Details

Form
EFFECT
Filing Date
Jul 23, 2020
Document Date
Jul 23, 2020
Form Description
EFFECT
Filing Group
Other
Company
iTeos Therapeutics
Issuer
ITEOS THERAPEUTICS, INC.

Filing Formats

View HTML
Download XLS
© 2021 iTeos Therapeutics. iTeos, iTeos logo and Cancer Immunotherapies By Design are trademarks of iTeos Therapeutics Inc.

Socials

LinkedIn Twitter

Footer Nav

Privacy policy Terms of use